Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
Clinical Pediatrics
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Pichichero, M. E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Pichichero, M. E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The Importance of Bacteriologic Eradication in the Treatment of Group A Streptococcal Tonsillopharyngitis

Michael E. Pichichero, MD

Departments of Microbiology and Immunology/ Pediatrics and Medicine, University of Rochester School of Medicine and Dentistry and Elmwood Pediatric Group, Rochester, New York, NY 14642, michael_ pichichero{at}urmc.rochester.edu

Eradication of the group A ß-hemolytic streptococci from the tonsillopharynx by use of antibiotics is the essential outcome to prevent suppurative and nonsuppurative sequelae, abate symptoms, and prevent contagion. The minimum criterion standard for eradication rate is 85% or better according to the United States Food and Drug Administration. From 1991 to present less than 20% of clinical trials have shown penicillin to meet or exceed the minimum standard compared with 100% for various cephalosporins, amoxicillin/clavulanate, and macrolides/azalides, when appropriately dosed. Efficacy alone cannot produce optimal treatment outcomes in clinical practice because nonadherence frequently results in failed therapy, persistence of infection, and morbidity. Poor taste and the need for 10 days of therapy with penicillin are adherence barriers. The evidence base supporting the selection of cephalosporins in preference to penicillin for treatment of group A ß-hemolytic streptococci tonsillopharyngitis is very strong (type A), and these agents have a better tolerability and adherence profile.

Key Words: group A streptococci • tonsillopharyngitis • penicillin

Clinical Pediatrics, Vol. 46, No. 4 suppl, 3S-16S (2007)
DOI: 10.1177/0009922807299719
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?